Evaxion Biotech A/S Investor Relations Material

Latest events

Q4 2023

Evaxion Biotech A/S

Q4 2023

2 Apr, 2024

R&D Day 2024

19 Mar, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Evaxion Biotech A/S

Access all reports
Evaxion Biotech utilizes the AI platform, which is designed to reduce the identification of novel epitopes, and to develop neoantigens, vaccines, and antibody-based therapies; pNLS platform that is designed to identify novel protein structures through computational design; and 2D-to-3D structural similarity searching algorithm. It is developing EB023, a peptide based immunotherapy for the treatment of head and neck cancer. Evaxion Biotech A/S was founded in 2008 and is headquartered in Copenhagen, Denmark.